Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2024
Business Overview: Vivos is a medical technology company developing non-surgical treatments for obstructive sleep apnea (OSA) and dentofacial abnormalities using "The Vivos Method." The company pivoted its strategy in 2024 from a dentist-centric enrollment model to a strategic alliance and acquisition model targeting sleep centers and medical providers. Key products include FDA-cleared oral appliances (C.A.R.E. devices) and diagnostic tools like the SleepImage home sleep test.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Total Revenue | $15,031 | $13,801 |
| Product Revenue | $7,874 | $6,270 |
| Service Revenue | $7,157 | $7,531 |
| Gross Profit | $9,019 | $8,271 |
| Gross Margin | 60% | 60% |
| Operating Loss | $(11,171) | $(17,296) |
| Net Loss | $(11,136) | $(13,583) |
| Cash and Cash Equivalents (End of Period) | $6,260 | $1,643 |
| Accumulated Deficit | $(104,187) | $(93,051) |
| Total Liabilities | $7,330 | $10,319 |
Liquidity: The company reported negative cash flow from operating activities of $12.7 million in 2024. Management states that current cash reserves are insufficient to fund operations for the next twelve months without additional financing.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 9% year-over-year, driven primarily by a 26% increase in product revenue (specifically Guide sales) and a reduction in discounts. Service revenue declined 5% due to a strategic shift away from VIP enrollment fees and changes in revenue recognition methodology regarding estimated customer lives.
- Expense Reduction: Operating expenses decreased significantly. General and Administrative (G&A) expenses dropped 20% to $17.9 million, and Sales and Marketing expenses fell 30% to $1.7 million, largely due to workforce reductions and reduced stock-based compensation.
- Non-Operating Items: The 2023 net loss was impacted by a $10.2 million gain from the change in fair value of warrant liabilities and a $6.5 million day-one warrant expense. These non-cash items were absent in 2024, making the operating loss the primary driver of the net loss.
- Capital Structure: The company raised approximately $19.2 million in gross proceeds through various private placements and registered direct offerings in 2024 (June, September, and December), significantly increasing cash on hand compared to the prior year.
Guidance, Outlook, and Risks
Strategic Pivot: Management is executing a pivot to an alliance-based model, exemplified by a strategic agreement with Rebis Health Holdings. The goal is to increase patient volume and revenue per case by integrating Vivos treatments directly into sleep centers rather than relying solely on independent dentists.
Outlook: The company anticipates continued losses and negative cash flow until revenue scales sufficiently. Management expects the new alliance model to drive top-line growth but notes that the model is in early stages with no assurance of success.
Key Risks and Contingencies:
- Going Concern: The auditor has issued a "Going Concern" opinion. The company explicitly states it requires additional financing to continue operations and meet Nasdaq listing requirements (specifically the $2.5 million stockholders' equity rule).
- Regulatory & Clinical: A clinical trial with Stanford University regarding the DNA appliance was placed on hold in late 2024 due to low recruitment. The company is working to resolve this, but delays could impact future FDA clearances.
- Market Confusion: The company faced reputational challenges in 2023-2024 due to media reports confusing its devices with a different, non-FDA cleared device (AGGA), which temporarily dampened sales.
- Internal Controls: While the company states it has remediated material weaknesses in internal controls identified in prior years, it remains an Emerging Growth Company with reduced disclosure requirements.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.3 million cash balance against the $12.7 million annual operating burn rate and the timeline for the next capital raise.
- Nasdaq Compliance: Monitor the company's ability to maintain the $2.5 million minimum stockholders' equity requirement to avoid delisting.
- Alliance Execution: Assess the actual revenue contribution from the Rebis Health alliance and any subsequent partnerships to validate the new business model.
- Clinical Trial Status: Track the status of the Stanford University clinical trial and the timeline for its resumption.
- Revenue Recognition: Review the impact of the revised "estimated customer life" assumptions on future service revenue recognition.